Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells
CNS Leukemia
Masonic Cancer Center, University of MinnesotaCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
20 Active assets in the CNS Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 3 | BB |
Daunorubicin Children's Oncology Group | Phase 3 | BB |
PEGASPARGASE Children's Oncology Group | Phase 3 | BB |
VINCRISTINE SULFATE Children's Oncology Group | Phase 3 | BB |
Inno-206 Children's Oncology Group | Phase 3 | BB |
View all 24 →
Same molecule, other indications
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →